Expected Moves

With cash reserves dropping to $7.7 million and a recent Nasdaq deficiency notice regarding negative equity, Adagio faces urgent capital needs. A highly dilutive secondary offering or convertible debt issuance is the base case.

Q3 results will center entirely on remaining liquidity, clinical trial burn from the FULCRUM-VT study, and management's final confidence heading into the pending PMA review for vCLAS.

The FDA is expected to complete its review of Adagio's Premarket Approval (PMA) application for the vCLAS Ventricular Ablation System. Management previously guided for a Q4 2026 decision.

The 180-day deadline to regain compliance with Nasdaq's $2.5 million stockholders' equity rule and $1.00 minimum bid price. A reverse stock split or desperate financing is probable if organic price action fails.

Following the anticipated Q4 FDA decision, this earnings print provides the first update on commercial launch strategy, initial electrophysiologist targeting, and 2027 CapEx guidance.

Q1 earnings will scrutinize the early commercial traction of vCLAS (if approved) and the pipeline progress of the next-generation ULTA system aiming for FULCRUM-VT trial completion.

Mid-year update assessing sustained vCLAS procedure volume, sequential revenue growth, and broader electrophysiology market penetration versus incumbent RF and standard cryoablation competitors.